UPDATED: Reata suggests Friedreich's ataxia program could be delayed, sending stock plunging

August 10, 2020 05:07 PM EDT; Reata Pharmaceuticals $RETA made waves last October when its drug omaveloxolone produced positive trial results in treating a rare neurological disorder, but the candidate’s path forward became much murkier Monday.
In a report of quarterly earnings, the biotech divulged that the FDA is considering delaying omaveloxolone’s NDA pending completion of a second trial. That could push back approval by at least a year given that the target population, individuals with Friedreich’s ataxia, is limited and progression of the hard-to-treat illness is notoriously slow. The Covid-19 pandemic would also hinder Reata’s ability to complete an additional trial.

FDA 'not convinced' MOXIe data sufficient

UPDATED: Reata suggests Friedreich's ataxia program could be delayed, sending stock plunging

Reata warns of indefinite delay to US filing for Friedreich's ataxia drug omaveloxolone